US9682968 — Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof
Composition of Matter · Assigned to Novartis AG · Expires 2034-07-14 · 8y remaining
What this patent protects
This patent protects a compound, specifically IPTACOPAN HYDROCHLORIDE, and methods for manufacturing it, as well as its therapeutic uses as a complement alternative pathway inhibitor.
USPTO Abstract
The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as inhibitors of the complement alternative pathway, in particular of Factor B. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.